Global Bone Cancer Drugs Market Set to Register a CAGR of Nearly 12% by 2023 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global
Bone Cancer Drugs Market 2019-2023” report has been added to ResearchAndMarkets.com’s
offering.

Small and medium sized pharmaceutical and biotechnology vendors in the
bone cancer market face a lack of funding to complete clinical trials
and launch drugs for the treatment of various bone cancer indications.
Pharmaceutical players face challenges with the distribution of drugs in
the regions where the vendor does not operate. To overcome such
challenges, these pharmaceutical companies are entering into strategic
alliances with local pharmaceutical vendors for the manufacturing and
distribution of drugs. The analysts have predicted that the bone cancer
drugs market will register a CAGR of nearly 12% by 2023.

Growing risk factors

Growing risk factors associated with bone cancer will drive market
growth in the forecast period. The growing prevalence of specific
cancers, where radiation therapy has been a dominant treatment, is
further stimulating market growth. Factors such as old age and family
history of bone cancer are common risk factors for the disease.

Preference of surgery

The most preferred treatment options available to patients with bone
cancer is surgeries, due to their remissive nature. Surgery for bone
cancer involves wide excision of the tumor, which includes removal of
the tumor along with a part of healthy tissue around the tumor in all
directions. The higher probability of recurrence of cancer tumors in the
future reduces patient adherence to drug treatment landscape which poses
a challenge to the market growth.

Competitive Landscape

The market appears to be concentrated and with the presence of a few
companies. Factors such as the growing risk factors and increasing
strategic alliances, will provide considerable growth opportunities to
bone cancer drugs manufactures.

Key Topics Covered:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 04: MARKET SIZING

• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

PART 06: PIPELINE

PART 07: MARKET SEGMENTATION BY INDICATION

• Market segmentation by indication
• Comparison by indication
• Osteosarcoma – Market size and forecast 2018-2023
• Ewing’s sarcoma – Market size and forecast 2018-2023
• Chondrosarcoma – Market size and forecast 2018-2023
• Others – Market size and forecast 2018-2023
• Market opportunity by indication

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2018-2023
• Europe – Market size and forecast 2018-2023
• Asia – Market size and forecast 2018-2023
• ROW – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

• Market drivers
• Market challenges

PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE

• Overview
• Landscape disruption
• Competitive scenario

PART 14: VENDOR ANALYSIS

• Vendors covered
• Vendor classification
• Market positioning of vendors
• Amgen
• Bayer AG
• Bristol-Myers Squibb Company
• Merck & Co. Inc.
• Pfizer Inc.

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international
market research reports and market data. We provide you with the latest
data on international and regional markets, key industries, the top
companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Oncology
Drugs